Erasca (ERAS) Competitors $2.42 +0.29 (+13.62%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$2.44 +0.02 (+0.83%) As of 10/3/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS vs. IDYA, BEAM, CDTX, IRON, AGIO, TVTX, BLTE, OCUL, ETNB, and ARQTShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include IDEAYA Biosciences (IDYA), Beam Therapeutics (BEAM), Cidara Therapeutics (CDTX), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), Travere Therapeutics (TVTX), Belite Bio (BLTE), Ocular Therapeutix (OCUL), 89BIO (ETNB), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Its Competitors IDEAYA Biosciences Beam Therapeutics Cidara Therapeutics Disc Medicine Agios Pharmaceuticals Travere Therapeutics Belite Bio Ocular Therapeutix 89BIO Arcutis Biotherapeutics Erasca (NASDAQ:ERAS) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment. Does the media prefer ERAS or IDYA? In the previous week, IDEAYA Biosciences had 1 more articles in the media than Erasca. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 3 mentions for Erasca. IDEAYA Biosciences' average media sentiment score of 1.02 beat Erasca's score of 0.40 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IDEAYA Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in ERAS or IDYA? 67.8% of Erasca shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 14.4% of Erasca shares are owned by company insiders. Comparatively, 2.5% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, ERAS or IDYA? Erasca has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Is ERAS or IDYA more profitable? Erasca's return on equity of -31.19% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -31.19% -26.34% IDEAYA Biosciences N/A -31.42%-29.45% Which has preferable earnings & valuation, ERAS or IDYA? Erasca has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$161.65M-$0.45-5.38IDEAYA Biosciences$7M346.05-$274.48M-$3.79-7.29 Do analysts rate ERAS or IDYA? Erasca currently has a consensus target price of $3.71, indicating a potential upside of 53.48%. IDEAYA Biosciences has a consensus target price of $43.36, indicating a potential upside of 56.86%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe IDEAYA Biosciences is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 2 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.38IDEAYA Biosciences 1 Sell rating(s) 3 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.72 SummaryIDEAYA Biosciences beats Erasca on 7 of the 13 factors compared between the two stocks. Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$686.48M$3.33B$6.08B$10.54BDividend YieldN/A2.27%5.68%4.70%P/E Ratio-5.3822.1478.0526.71Price / SalesN/A421.73579.79179.45Price / CashN/A47.2037.7961.25Price / Book1.619.9312.556.56Net Income-$161.65M-$52.80M$3.31B$277.70M7 Day Performance16.35%5.22%4.28%2.41%1 Month Performance63.51%13.01%7.85%9.30%1 Year Performance-4.72%25.18%71.37%31.22% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca2.1385 of 5 stars$2.42+13.6%$3.71+53.5%-1.2%$686.48MN/A-5.38120News CoverageHigh Trading VolumeIDYAIDEAYA Biosciences4.3072 of 5 stars$27.19+1.3%$43.36+59.5%-5.5%$2.35B$7M-7.1780Positive NewsAnalyst UpgradeBEAMBeam Therapeutics2.8929 of 5 stars$23.91+4.1%$46.40+94.1%+12.2%$2.32B$63.52M-5.31510Positive NewsCDTXCidara Therapeutics3.9711 of 5 stars$95.26+5.3%$119.43+25.4%+853.2%$2.29B$1.27M-8.5690Analyst ForecastHigh Trading VolumeIRONDisc Medicine2.0183 of 5 stars$65.06-0.7%$98.30+51.1%+35.2%$2.28BN/A-14.5530AGIOAgios Pharmaceuticals4.3654 of 5 stars$39.27+0.9%$56.00+42.6%-0.1%$2.26B$40.88M3.57390Insider TradeTVTXTravere Therapeutics2.3935 of 5 stars$24.04-5.0%$34.20+42.3%+80.5%$2.26B$233.18M-11.78460Analyst UpgradeBLTEBelite Bio3.0221 of 5 stars$73.00+4.3%$96.00+31.5%+48.5%$2.23BN/A-47.1010Positive NewsOCULOcular Therapeutix4.0117 of 5 stars$12.53flat$17.83+42.3%+23.6%$2.18B$63.72M-9.79230Trending NewsAnalyst ForecastAnalyst RevisionGap UpETNB89BIO3.136 of 5 stars$14.70flat$25.81+75.6%+107.4%$2.18BN/A-4.0740Options VolumeARQTArcutis Biotherapeutics1.3677 of 5 stars$18.62+6.0%$19.80+6.3%+95.8%$2.11B$196.54M-24.83150Trending NewsInsider TradeHigh Trading Volume Related Companies and Tools Related Companies IDEAYA Biosciences Alternatives Beam Therapeutics Alternatives Cidara Therapeutics Alternatives Disc Medicine Alternatives Agios Pharmaceuticals Alternatives Travere Therapeutics Alternatives Belite Bio Alternatives Ocular Therapeutix Alternatives 89BIO Alternatives Arcutis Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERAS) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredChina’s New Gold Play Could Make your Income SoarChina's New Gold Move Could Pay You up to $1,152/month. China just announced plans to store other nations' ...Investors Alley | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredLost Decade warning – do this nowWith the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter ...Porter & Company | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ERAS Stock Alerts